MFMireya Fuentes

Mireya Fuentes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mireya Fuentes has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Jordi Roca-Ferrer

    Immunoallèrgia Respiratòria Clínica i Experimental, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    10 shared publications
  • Laura Pujols

    IDIBAPS & CIBERES, Barcelona, Spain

    7 shared publications
  • Isam Alobid

    Clinical and Experimental Respiratory Immunoallergy, Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERes), Barcelona, Spain; Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain

    6 shared publications
  • Joaquim Mullol

    Clinical and Experimental Respiratory Immunoallergy, Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERes), Barcelona, Spain; Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain

    6 shared publications
  • César Picado

    Clinical and Experimental Respiratory Immunoallergy, Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERes), Barcelona, Spain; Allergy Unit, Pneumology and Allergy Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

    5 shared publications
  • Laura Fernández-Bertolín

    Clinical and Experimental Respiratory Immunoallergy, Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERes), Barcelona, Spain

    4 shared publications

Latest Publications

  • Open Access

    Effect of Lipopolysaccharide on Glucocorticoid Receptor Function in Control Nasal Mucosa Fibroblasts and in Fibroblasts from Patients with Chronic Rhinosinusitis with Nasal Polyps and Asthma

    by Laura Fernández-Bertolín, Joaquim Mullol, Mireya Fuentes-Prado, Jordi Roca-Ferrer, Isam Alobid, César Picado, Laura Pujols

    Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease of the upper airways frequently associated with asthma. Bacterial infection is a feature of CRSwNP that can aggravate the disease and the response to glucocorticoid treatment. We examined whether the bacterial product lipopolysaccharide (LPS) reduces glucocorticoid receptor (GR) function in control nasal mucosa (NM) fibroblasts and in nasal polyp (NP) fibroblasts from patients with CRSwNP and asthma. NP (n = 12) and NM fibroblasts (n = 10) were in vitro pre-incubated with LPS (24 hours) prior to the addition of dexamethasone. Cytokine/chemokine secretion was measured by ELISA and Cytometric Bead Array. GRα, GRβ, mitogen-activated protein-kinase phosphatase-1 (MKP-1) and glucocorticoid-induced leucine zipper (GILZ) expression was measured by RT-PCR and immunoblotting, GRα nuclear translocation by immunocytochemistry, and GRβ localization by immunoblotting. The role of MKP-1 and GILZ on dexamethasone-mediated cytokine inhibition was analyzed by small interfering RNA silencing. Pre-incubation of nasal fibroblasts with LPS enhanced the secretion of IL-6, CXCL8, RANTES, and GM-CSF induced by FBS. FBS-induced CXCL8 secretion was higher in NP than in NM fibroblasts. LPS effects on IL-6 and CXCL8 were mediated via activation of p38α/β MAPK and IKK/NF-κB pathways. Additionally, LPS pre-incubation: 1) reduced dexamethasone’s capacity to inhibit FBS-induced IL-6, CXCL8 and RANTES, 2) reduced dexamethasone-induced GRα nuclear translocation (only in NM fibroblasts), 3) did not alter GRα/GRβ expression, 4) decreased GILZ expression, and 5) did not affect dexamethasone’s capacity to induce MKP-1 and GILZ expression. MKP-1 knockdown reduced dexamethasone’s capacity to suppress FBS-induced CXCL8 release. The bacterial product LPS negatively affects GR function in control NM and NP fibroblasts by interfering with the capacity of the activated receptor to inhibit the production of pro-inflammatory mediators. This study contributes to the understanding of how bacterial infection of the upper airways may limit the efficacy of glucocorticoid treatment.


  • Open Access

    Reconstituted Human Upper Airway Epithelium as 3-D In Vitro Model for Nasal Polyposis

    by Francisco De Borja Callejas, Asunción Martínez-Antón, Isam Alobid, Mireya Fuentes, Julio Cortijo, César Picado, Jordi Roca-Ferrer, Joaquim Mullol

    Primary human airway epithelial cells cultured in an air-liquid interface (ALI) develop a well-differentiated epithelium. However, neither characterization of mucociliar differentiation overtime nor the inflammatory function of reconstituted nasal polyp (NP) epithelia have been described. 1st) To develop and characterize the mucociliar differentiation overtime of human epithelial cells of chronic rhinosinusitis with nasal polyps (CRSwNP) in ALI culture system; 2nd) To corroborate that 3D in vitro model of NP reconstituted epithelium maintains, compared to control nasal mucosa (NM), an inflammatory function. Epithelial cells were obtained from 9 NP and 7 control NM, and differentiated in ALI culture for 28 days. Mucociliary differentiation was characterized at different times (0, 7, 14, 21, and 28 days) using ultrastructure analysis by electron microscopy; ΔNp63 (basal stem/progenitor cell), β-tubulin IV (cilia), and MUC5AC (goblet cell) expression by immunocytochemistry; and mucous (MUC5AC, MUC5B) and serous (Lactoferrin) secretion by ELISA. Inflammatory function of ALI cultures (at days 0, 14, and 28) through cytokine (IL-8, IL-1β, IL-6, IL-10, TNF-α, and IL-12p70) and chemokine (RANTES, MIG, MCP-1, IP-10, eotaxin-1, and GM-CSF) production was analysed by CBA (Cytometric Bead Array). In both NP and control NM ALI cultures, pseudostratified epithelium with ciliated, mucus-secreting, and basal cells were observed by electron microscopy at days 14 and 28. Displaying epithelial cell re-differentation, β-tubulin IV and MUC5AC positive cells increased, while ΔNp63 positive cells decreased overtime. No significant differences were found overtime in MUC5AC, MUC5B, and lactoferrin secretions between both ALI cultures. IL-8 and GM-CSF were significantly increased in NP compared to control NM regenerated epithelia. Reconstituted epithelia from human NP epithelial cells cultured in ALI system provides a 3D in vitro model that could be useful both for studying the role of epithelium in CRSwNP while developing new therapeutic strategies, including cell therapy, for CRSwNP.


  • Fluticasone Furoate Inhibits Cytokine Secretion from Nasal Epithelial Cells and Reduces Eosinophil Survival in an in vitro Model of Eosinophilic Inflammation

    by Joaquim Mullol, Laura Pujols, Isam Alobid, Maria Pérez-Gonzalez, Mireya Fuentes, Francisco de Borja Callejas, Antonio Valero, Cesar Picado, Jordi Roca-Ferrer

    Background: Fluticasone furoate (FF) is an intranasal corticosteroid indicated for the treatment of allergic rhinitis (AR). However, the anti-inflammatory effects of FF in the nasal mucosa have yet to be investigated thoroughly. The aim of this study was to investigate the effect of FF on eosinophil survival and cytokine secretion from nasal mucosa epithelial cells. Methods: Epithelial cells obtained from nasal mucosa were stimulated with 10% fetal bovine serum (FBS) in the presence of FF (from 10-12 to 10-7M) for 6-24 h. Cytokine [granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-6 and IL-8] concentrations in supernatants were measured by ELISA. Peripheral blood eosinophils were incubated for 4 days with epithelial cell secretions in the presence or absence of FF (from 10-12 to 10-7M) and survival was assessed by Trypan blue dye exclusion. Results are expressed as medians of the minimum effective concentration and IC values. Results: FBS stimulated the secretion of GM-CSF, IL-6 and IL-8. FF significantly inhibited GM-CSF (up to 10-10M, IC25 = 12.6 pM), IL-6 (up to 10-10M, IC25 = 65.8 pM) and IL-8 (up to 10-11M, IC25 = 8.6 pM) secretion induced by FBS (n = 8). Epithelial cell secretions induced eosinophil survival from day 1 to day 4 (n = 6). This effect was significantly inhibited by FF (up to 10-12M) at day 3 (IC50 = 3.22 nM) and day 4 (IC50 = 1.29 nM). Conclusions: The results obtained in this in vitro model suggest that FF may reduce upper airway eosinophilic inflammation through decreasing cytokine secretion from epithelial cells and reducing eosinophil survival.


  • Deficient glucocorticoid induction of anti-inflammatory genes in nasal polyp fibroblasts of asthmatic patients with and without aspirin intolerance

    by Laura Fernández-Bertolín, Joaquim Mullol, Mireya Fuentes-Prado, Isam Alobid, Jordi Roca-Ferrer, César Picado, Laura Pujols


  • Open Access

    Proteasome Inhibition Reduces Proliferation, Collagen Expression, and Inflammatory Cytokine Production in Nasal Mucosa and Polyp Fibroblasts

    by Laura Pujols, Laura Fernández-Bertolín, Mireya Fuentes-Prado, Isam Alobid, Jordi Roca-Ferrer, Neus Agell, Joaquim Mullol, César Picado

    Proteasome inhibitors, used in cancer treatment for their proapoptotic effects, have anti-inflammatory and antifibrotic effects on animal models of various inflammatory and fibrotic diseases. Their effects in cells from patients affected by either inflammatory or fibrotic diseases have been poorly investigated. Nasal polyposis is a chronic inflammatory disease of the sinus mucosa characterized by tissue inflammation and remodeling. We tested the hypothesis that proteasome inhibition of nasal polyp fibroblasts might reduce their proliferation and inflammatory and fibrotic response. Accordingly, we investigated the effect of the proteasome inhibitor Z-Leu-Leu-Leu-B(OH)(2) (MG262) on cell viability and proliferation and on the production of collagen and inflammatory cytokines in nasal polyp and nasal mucosa fibroblasts obtained from surgery specimens. MG262 reduced the viability of nasal mucosa and polyp fibroblasts concentration- and time-dependently, with marked effects after 48 h of treatment. The proteasome inhibitor bortezomib provoked a similar effect. MG262-induced cell death involved loss of mitochondrial membrane potential, caspase-3 and poly(ADP-ribose) polymerase activation, induction of c-Jun phosphorylation, and mitogen-activated protein kinase phosphatase-1 expression. Low concentrations of MG262 provoked growth arrest, inhibited DNA replication and retinoblastoma phosphorylation, and increased expression of the cell cycle inhibitors p21 and p27. MG262 concentration-dependently inhibited basal and transforming growth factor-β-induced collagen mRNA expression and interleukin (IL)-1β-induced production of IL-6, IL-8, monocyte chemoattractant protein-1, regulated on activation normal T cell expressed and secreted, and granulocyte/macrophage colony-stimulating factor in both fibroblast types. MG262 inhibited IL-1β/tumor necrosis factor-α-induced activation of nuclear factor-κB. We conclude that noncytotoxic treatment with MG262 reduces the proliferative, fibrotic, and inflammatory response of nasal fibroblasts, whereas high MG262 concentrations induce apoptosis.


  • Lower sensitivity of nasal polyp fibroblasts to glucocorticoid anti-proliferative effects

    by Laura Pujols, Mireya Fuentes-Prado, Laura Fernández-Bertolín, Isam Alobid, Jordi Roca-Ferrer, Joaquim Mullol, César Picado


    • 1 October 2010
      • Vol. 24  (4) , 403-411

    MONTELUKAST REDUCES EOSINOPHILIC INFLAMMATION BY INHIBITING BOTH EPITHELIAL CELL CYTOKINE SECRETION (GM-CSF, IL-6, IL-8) AND EOSINOPHIL SURVIVAL

    by J. Mullol, F. B. Callejas, E. Mendez-Arancibia, M. Fuentes, I. Alobid, A. Martinez-Anton, A. Valero, C. Picado, J. Roca-Ferrer

    Leukotriene receptor antagonists, such as montelukast (MK), are currently used to treat rhinitis and asthma, but their anti-inflammatory role in eosinophil inflammation is not well understood. The aim of this study is to investigate the effect of MK on an in vitro model of upper-airway eosinophil inflammation by reducing pro-inflammatory cytokines from both nasal mucosa (NM) and polyp (NP) epithelial cells and reducing eosinophil survival primed by epithelial cell secretions. Epithelial cells were stimulated with fetal bovine serum (FBS) with/without MK for 24 hours, and cytokine concentrations in epithelial secretions were measured by ELISA. After incubating peripheral blood eosinophils with epithelial cell-conditioned media (ECM) with/without MK up to 3 days, eosinophil survival was assessed by Trypan blue dye exclusion. Results are expressed as mean +/- SEM of cytokine concentration (% of control) or eosinophil survival (%). Epithelial cell stimulation increased GM-CSF, IL-6, IL-8, and sICAM-1 secretion in both NM and NP. MK had a significant inhibitory effect on FBS-induced GM-CSF, IL-6, and IL-8 secretion, but not sICAM-1, in both NM and NP. MK also showed an inhibitory effect (p<0.05) on ECM-induced eosinophil survival from both NM (from 10(-5)M to 10(-7)M, n=7) and NP (at 10(-5)M, n=7), after 3 days of incubation. These anti-inflammatory effects on epithelial cell cytokine secretion and on eosinophil survival suggest that montelukast may contribute to the reduction of eosinophilic inflammation in upper-airway inflammatory diseases such as rhinitis and nasal polyposis.


  • Effect of budesonide and nedocromil sodium on IL-6 and IL-8 release from human nasal mucosa and polyp epithelial cells

    by A Xaubet, J Mullol, J Roca-Ferrer, L Pujols, M Fuentes, M Pérez, J.M Fabra, C Picado


  • Regulation of cyclooxygenase‐1 and ‐2 expression in human nasal mucosa. Effects of cytokines and dexamethasone

    by Fernández‐ Morata, J Mullol, M Fuentes, L Pujols, Roca‐ Ferrer, M Pérez, A Xaubet, C Picado

    Background: Cyclooxygenase (COX) converts arachidonic acid in prostanoids. COX exists in two isoforms, COX‐1 is the constitutive whereas COX‐2 is the inducible isoform. The regulation of COX‐1 and COX‐2 expression in nasal mucosa has not been previously reported.Aim: We studied expression and regulation by cytokines and corticosteroids of COX‐1 and COX‐2 in human nasal mucosa. Cultured human nasal explants from patients undergoing corrective nasal mucosal resection were examined for COX‐1 and COX‐2 expression by semiquantitative competitive PCR and Western blot.Methods: Explants were incubated with pro‐(IFNγ, IL‐1β, and TNF‐α) and anti(IL‐10) inflammatory cytokines and dexamethasone. The mechanisms which regulate COX‐2 mRNA expression were studied using inhibitors of translation (Actinomycin D) and transcription (Cicloheximide).Results: The baseline expression of COX‐2 mRNA was higher than COX‐1 mRNA. Once in culture, there was a slight spontaneous up‐regulation of COX‐1 and a strong COX‐2 mRNA and protein up‐regulation. The incubation of nasal explants with pro‐inflammatory cytokines increased the expression of COX‐2 mRNA and protein, from 1 to 24 h of incubation in a dose‐related manner. The regulation of these effects occurred at both transcriptional and post‐transcriptional levels. Dexamethasone and IL‐10 abrogated cytokine‐induced COX‐2 mRNA and protein expression. Pro‐inflammatory cytokines, dexamethasone and IL‐10 had no effect on COX‐1 mRNA expression.Conclusions: As prostanoids have important regulatory effects on the immunologically mediated inflammatory responses, our findings throw some light on the mechanisms that regulate the enzymes which produce these metabolites in the human airway.


  • Regulation of ICAM‐3 and other adhesion molecule expressions on eosinophils in vitro. Effects of dexamethasone

    by M. Juan, C. Vilardell, J. Yagüe, C. Picado, J. Mullol, J. Roca‐Ferrer, M. Fuentes, M. Pérez

    Background: ICAM‐3 has been recently identified as the third leukocyte‐function associated‐1 (LFA‐1) ligand. ICAM‐3 is expressed in eosinophils, but its regulation has not been studied. The objectiv...